2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research…
Kate O’NeillFebruary 23, 2023
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for…
Kate O’NeillDecember 5, 2022
innovation Detection of any cognitive impairment as part of the Affordable Care Act’s annual wellness…
adminMarch 30, 2022
Detection of any cognitive impairment as part of the Affordable Care Act’s annual wellness visit…
adminFebruary 18, 2022
In a study led by the LuMind IDSC Foundation, the T21RS COVID-19 Initiative launched an…
adminJanuary 26, 2022
Recently, two institutions in the Down Syndrome Clinical Trials Network (DS-CTN) published five studies about Down syndrome-related…
adminJanuary 25, 2022
During the past year, LuMind IDSC remained cautiously optimistic about treatment possibilities that the development…
adminJanuary 12, 2022
Dr. Nicole White, Hampus Hillerstrom, LuMind IDSC and a team of experts, recently published an…
adminOctober 18, 2021
Dr. James Hendrix, LuMind IDSC's Chief Scientific Officer, along with a team of Down syndrome…
Kate O’NeillOctober 13, 2021